一种酪蛋白激酶1δ抑制剂在制备青光眼及高眼压症治疗药物中的应用
By using the casein kinase 1δ inhibitor WAY-647766 to reverse IFN-γ-induced trabecular meshwork cell death, the problem of elevated intraocular pressure in glaucoma was resolved, achieving the effects of reducing intraocular pressure and protecting retinal ganglion cells.
CN122182781BActive Publication Date: 2026-07-17THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
- Filing Date
- 2026-05-14
- Publication Date
- 2026-07-17
Smart Images
Figure CN122182781B_ABST
Abstract
本发明属于医药技术领域，具体涉及一种酪蛋白激酶1δ抑制剂在制备青光眼及高眼压症治疗药物中的应用，所述酪蛋白激酶1δ抑制剂即CK1δ抑制剂为选自如下八种化合物中的任意一种，WAY‑630363、WAY‑632323、WAY‑607777、WAY‑348144、WAY‑631127、WAY‑639932、WAY‑650313、WAY‑647766。本发明所述的八种CK1δ抑制剂区别于目前广泛应用的CK1δ抑制剂和泛CK1抑制剂，本发明所述的八种CK1δ抑制剂可有效逆转小梁网细胞的死亡，从而降低眼压并减少视网膜神经节细胞的损失。
Need to check novelty before this filing date? Find Prior Art